ARTThe name ofthe drug thatsuppressedHIV toundetectableamountsAMPTrialName of thetrial thatused VRC01bNAbMF59AdjuvantThe adjuvantthat wasused in theHVTN702trialSTEPThe name of theclinical trial that tookplace around thesame time as theSTEP trial andattempted to induceCD8+ T cell response(terminated now)MosaicvaccinedesignNew vaccineapproach thathopes to maximizeT-cell epitopes anduses artificiallyconstructedantigens4injections/halfyearDosagefor RV144trialNeutralizingantibodiesApproach forHIV vaccine thattargeted gp120and gp160 andworked for HepB vaccine69%Number of HIV+patients achievedcompletechimerism at 6months post-transplantRV144The name of theclinical trial that isnow consideredthe milestoneevent in HIVvaccine researchIAVIG001Name of the phase1 trial of the mRNA-based vaccine, wasfound to activategermline to producethe correct bNAbsmRNAbasedvaccinetechnologyNew vaccineapproach that usesRNA to produce viralprotein to instigate animmune response.Method was used toproduce COVIDvaccinePrimeBoostStrategiesVaccine approachused by RV144 trialthat involved theuse of a viralvector+recombinantproteinHIVconsvVaccineNew vaccineapproach thathopes to induce Tcell response.Notable trialsinclude HIV-CORE004HepatitisBNeutralizingantibodies wereused to createa successfulvaccine for thisdisease:CD8+T-cellName of cell thatwas found to havea significantdecrease after anHIV infection,response targetedin STEP trial15%Percentage ofHIV transmittednon-sexually(needles,blood, motherto child)85%Percentageof HIVtransmittedsexuallyHVTN702Clinical trial built onRV144, specifyingto clades in SouthAfrica andattempted toincrease efficacy ofRV144gp120Theglycoproteinthat wastargeted by theVAX 003 and004 trials100%percentage ofpatients hadundetectable HIVDNA in their bloodcells with completechimerismAlumadjuvantThe adjuvantthat wasused in theRV144 trialHIV-CORE004Name of thephase 1 trialfor theHIVconsvvaccinebNAbThe name of theapproach ofusing antibodiesthat recognizinga wide range ofHIV-1 strains3How manypatients dieddue to non-relapsecauses?Relapse ofmalignancy(cancer)the primary causeof treatment failurein the AllogeneicHematopoietic CellTransplant study24.4monthsmedianfollow-uptime forsurvivors inthis studyCOVIDmRNA-basedvaccinetechnology wasused to create asuccessful vaccinefor this disease:APPROACHThe name of theclinical trial for theMosaic VaccineDesign that showedsome success forvectors Ad26 andMVAPrEPThe name ofthe currentHIVpreventativedrugARTThe name ofthe drug thatsuppressedHIV toundetectableamountsAMPTrialName of thetrial thatused VRC01bNAbMF59AdjuvantThe adjuvantthat wasused in theHVTN702trialSTEPThe name of theclinical trial that tookplace around thesame time as theSTEP trial andattempted to induceCD8+ T cell response(terminated now)MosaicvaccinedesignNew vaccineapproach thathopes to maximizeT-cell epitopes anduses artificiallyconstructedantigens4injections/halfyearDosagefor RV144trialNeutralizingantibodiesApproach forHIV vaccine thattargeted gp120and gp160 andworked for HepB vaccine69%Number of HIV+patients achievedcompletechimerism at 6months post-transplantRV144The name of theclinical trial that isnow consideredthe milestoneevent in HIVvaccine researchIAVIG001Name of the phase1 trial of the mRNA-based vaccine, wasfound to activategermline to producethe correct bNAbsmRNAbasedvaccinetechnologyNew vaccineapproach that usesRNA to produce viralprotein to instigate animmune response.Method was used toproduce COVIDvaccinePrimeBoostStrategiesVaccine approachused by RV144 trialthat involved theuse of a viralvector+recombinantproteinHIVconsvVaccineNew vaccineapproach thathopes to induce Tcell response.Notable trialsinclude HIV-CORE004HepatitisBNeutralizingantibodies wereused to createa successfulvaccine for thisdisease:CD8+T-cellName of cell thatwas found to havea significantdecrease after anHIV infection,response targetedin STEP trial15%Percentage ofHIV transmittednon-sexually(needles,blood, motherto child)85%Percentageof HIVtransmittedsexuallyHVTN702Clinical trial built onRV144, specifyingto clades in SouthAfrica andattempted toincrease efficacy ofRV144gp120Theglycoproteinthat wastargeted by theVAX 003 and004 trials100%percentage ofpatients hadundetectable HIVDNA in their bloodcells with completechimerismAlumadjuvantThe adjuvantthat wasused in theRV144 trialHIV-CORE004Name of thephase 1 trialfor theHIVconsvvaccinebNAbThe name of theapproach ofusing antibodiesthat recognizinga wide range ofHIV-1 strains3How manypatients dieddue to non-relapsecauses?Relapse ofmalignancy(cancer)the primary causeof treatment failurein the AllogeneicHematopoietic CellTransplant study24.4monthsmedianfollow-uptime forsurvivors inthis studyCOVIDmRNA-basedvaccinetechnology wasused to create asuccessful vaccinefor this disease:APPROACHThe name of theclinical trial for theMosaic VaccineDesign that showedsome success forvectors Ad26 andMVAPrEPThe name ofthe currentHIVpreventativedrug

Journal Club - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
  1. The name of the drug that suppressed HIV to undetectable amounts
    ART
  2. Name of the trial that used VRC01 bNAb
    AMP Trial
  3. The adjuvant that was used in the HVTN702 trial
    MF59 Adjuvant
  4. The name of the clinical trial that took place around the same time as the STEP trial and attempted to induce CD8+ T cell response (terminated now)
    STEP
  5. New vaccine approach that hopes to maximize T-cell epitopes and uses artificially constructed antigens
    Mosaic vaccine design
  6. Dosage for RV144 trial
    4 injections/half year
  7. Approach for HIV vaccine that targeted gp120 and gp160 and worked for Hep B vaccine
    Neutralizing antibodies
  8. Number of HIV+ patients achieved complete chimerism at 6 months post-transplant
    69%
  9. The name of the clinical trial that is now considered the milestone event in HIV vaccine research
    RV144
  10. Name of the phase 1 trial of the mRNA-based vaccine, was found to activate germline to produce the correct bNAbs
    IAVI G001
  11. New vaccine approach that uses RNA to produce viral protein to instigate an immune response. Method was used to produce COVID vaccine
    mRNA based vaccine technology
  12. Vaccine approach used by RV144 trial that involved the use of a viral vector+recombinant protein
    Prime Boost Strategies
  13. New vaccine approach that hopes to induce T cell response. Notable trials include HIV-CORE 004
    HIVconsv Vaccine
  14. Neutralizing antibodies were used to create a successful vaccine for this disease:
    Hepatitis B
  15. Name of cell that was found to have a significant decrease after an HIV infection, response targeted in STEP trial
    CD8+ T-cell
  16. Percentage of HIV transmitted non-sexually (needles, blood, mother to child)
    15%
  17. Percentage of HIV transmitted sexually
    85%
  18. Clinical trial built on RV144, specifying to clades in South Africa and attempted to increase efficacy of RV144
    HVTN 702
  19. The glycoprotein that was targeted by the VAX 003 and 004 trials
    gp120
  20. percentage of patients had undetectable HIV DNA in their blood cells with complete chimerism
    100%
  21. The adjuvant that was used in the RV144 trial
    Alum adjuvant
  22. Name of the phase 1 trial for the HIVconsv vaccine
    HIV-CORE 004
  23. The name of the approach of using antibodies that recognizing a wide range of HIV-1 strains
    bNAb
  24. How many patients died due to non-relapse causes?
    3
  25. the primary cause of treatment failure in the Allogeneic Hematopoietic Cell Transplant study
    Relapse of malignancy (cancer)
  26. median follow-up time for survivors in this study
    24.4 months
  27. mRNA-based vaccine technology was used to create a successful vaccine for this disease:
    COVID
  28. The name of the clinical trial for the Mosaic Vaccine Design that showed some success for vectors Ad26 and MVA
    APPROACH
  29. The name of the current HIV preventative drug
    PrEP